📰 Merck Sharp News
Page 80 - Merck Sharp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Merck Sharp. Real-time updates on events, politics, business and more.
February 18, 2022
Comprehensive molecular profiling can guide treatment for rare cancers as well as it does for non-rare cancers, new research suggests.
February 17, 2022
- Data From ARTISTRY-1 Clinical Trial Highlight Single-Agent, Anti-Tumor Activity of Nemvaleukin in Patients With Renal Cell Carcinoma - DUBLIN, Feb. 17, 2022 /PRNewswire/ -- Alkermes
February 17, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new data from the ongoing phase 1/2 ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin),...
February 16, 2022
-- Revenues of $1.17 Billion in 2021, GAAP Loss per Share of $0.30 and Diluted Non-GAAP Earnings per Share of $0.78 -- -- Financial Expectations for 2022 and Updated Long-Term Profitability
February 16, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations...
February 16, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2021 and provided financial expectations...
February 14, 2022
The event-free survival rate was higher with neoadjuvant pembrolizumab plus chemotherapy, compared with chemotherapy alone.
February 12, 2022
Invasive aspergillosis (IA) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
February 12, 2022
Researchers found that at 36 months, the estimated event-free survival was 84.5 and 76.8% in the pembrolizumab-chemotherapy and placebo-chemotherapy groups, respectively.